How to Track a Prior Authorization Without Losing Weeks

A prior authorization, usually shortened to PA, is the approval your insurer requires before it will pay for a biologic or other advanced therapy. The request moves through at least four hands: your gastroenterology practice, the insurer or its pharmacy benefit manager, sometimes a specialty pharmacy, and finally an infusion center or your front door. Nobody in that chain owns the whole timeline, and a request that stalls at any handoff can sit untouched for a week before anyone notices. Learning how to track a prior authorization means knowing what deadline applies, who is holding the file today, and what the next event is supposed to be.

The delay is measurable. In a study of 411 patients starting biologic therapy, the median time from prescription to first dose was 20 days, ranging from 10 days for adalimumab to 21 days for vedolizumab and ustekinumab. Across two centers starting advanced IBD therapies, only 46.6% of 388 patients received a first dose within 14 days, and an initial insurance denial nearly tripled the odds of delay.

Know Which Deadline Applies to Your Plan

The single most useful thing a patient can write down is the legal turnaround clock for their specific plan type, because "we are still waiting on the insurance" means very different things depending on coverage.

If you have an employer-sponsored plan governed by federal ERISA rules, a pre-service claim that is not urgent must be decided no later than 15 days after receipt, extendable once by 15 more days, while an urgent care claim must be decided within 72 hours. If the plan asks you for more information, you get at least 45 days to supply it, and the clock pauses in the meantime. Medicaid managed care plans must issue a standard service authorization decision within 7 calendar days for rating periods beginning January 1, 2026 or later, with expedited decisions due within 72 hours and extensions capped at 14 additional days. Medicare Advantage plans have 14 calendar days for a standard organization determination, and for expedited requests 72 hours, shortened to 24 hours for Part B drugs with no extension permitted. If the drug runs through your pharmacy benefit under Medicare Part D, the sponsor must decide a standard coverage determination no later than 72 hours after receiving the request.

Build a Tracker With Four Anchor Facts

A workable prior authorization tracker fits on one page and holds four things for every request. The first is the submission date and the reference number the insurer assigns, which is the only identifier that lets a phone representative find your file quickly. The second is the applicable decision deadline, calculated from the submission date using the rule above, written as a calendar date rather than a number of days. The third is the current holder, meaning the specific party you last confirmed had the ball: the prescriber's office, the plan's clinical review team, or the specialty pharmacy. The fourth is the next scheduled event, such as a promised callback, a peer-to-peer review slot, or a shipment date.

Update the tracker only with confirmed facts. Log the name of every person you speak to, the date, and what they committed to do. When a representative says a decision is pending, ask what specific item is outstanding and what date the decision will be issued, then write both answers down verbatim.

How to Check Prior Authorization Status Without Guesswork

Call the member services number on your insurance card and ask for the utilization management or prior authorization department, then give the reference number. Ask whether the request has been received, whether it is complete, and whether any clinical documentation is outstanding. If the answer is that documentation is missing, that is the moment to call the prescriber's office with the exact list, because a request marked incomplete may not be running against any deadline at all.

If your biologic is dispensed through a specialty pharmacy, that pharmacy is a separate tracking node. Approval by the insurer does not mean the drug has shipped, and the pharmacy may be waiting on benefits verification, copay assistance enrollment, or a nursing visit. In one study, sites without an embedded pharmacy team were more than five times as likely to have delayed starts, and intravenous therapy carried a threefold higher risk of delay than self-administered options. If your care team has a prior authorization specialist or pharmacist, ask for that person by name and make them a standing contact.

Escalate on the Deadline, Not After It

When the decision date passes without an answer, escalate the same day. Federal rules give you a route. For non-grandfathered plans, internal appeals of urgent care claims must be resolved within 72 hours, plans must share any new evidence they relied on before issuing a final adverse determination, and expedited external review is available when standard timelines would seriously jeopardize your health or your ability to regain maximum function.

Escalation works more often than patients expect. In a national survey of pediatric IBD care, prior authorization was required for 81% of patients, yet 77% of initial denials were ultimately approved after appeal or peer-to-peer review. Ask your gastroenterologist's office to request a peer-to-peer review, and ask the insurer directly whether your request qualifies for expedited handling based on active disease.

What the Lost Weeks Cost

The clinical case for tracking is not abstract. Among pediatric IBD patients facing payer barriers, 60% experienced adverse outcomes or worsened quality of life and 21% were hospitalized because of treatment delays. A separate analysis found that a standard prior authorization added roughly 10 days to biologic initiation and a complicated one added about 25 days, with prior authorization associated with a 14.1% increased likelihood of corticosteroid dependence at 90 days and roughly one preventable hospitalization, surgery, or emergency visit for every eight patients delayed. Delay is also unevenly distributed: mean time to approval was 19.4 days for privately insured patients compared with 49.1 days on Medicaid and 52.7 days on Medicare.

The goal of IBD drug therapy is to reduce inflammation and bring on and maintain remission, and every week a prescribed therapy sits in an administrative queue is a week that goal is deferred. A one-page tracker holding submission dates, reference numbers, deadlines, named contacts and promised callbacks converts a process you cannot control into one you can at least observe. Patients who know the exact date their insurer owes them an answer make one phone call on that date instead of discovering a month later that a fax was never received.